These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

546 related articles for article (PubMed ID: 30252531)

  • 1. The Influence of Industry Sponsorship on the Research Agenda: A Scoping Review.
    Fabbri A; Lai A; Grundy Q; Bero LA
    Am J Public Health; 2018 Nov; 108(11):e9-e16. PubMed ID: 30252531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Industry sponsorship and research outcome.
    Lundh A; Sismondo S; Lexchin J; Busuioc OA; Bero L
    Cochrane Database Syst Rev; 2012 Dec; 12():MR000033. PubMed ID: 23235689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Industry sponsorship and research outcome.
    Lundh A; Lexchin J; Mintzes B; Schroll JB; Bero L
    Cochrane Database Syst Rev; 2017 Feb; 2(2):MR000033. PubMed ID: 28207928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scope and impact of financial conflicts of interest in biomedical research: a systematic review.
    Bekelman JE; Li Y; Gross CP
    JAMA; 2003 Jan 22-29; 289(4):454-65. PubMed ID: 12533125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Industry funding of patient and health consumer organisations: systematic review with meta-analysis.
    Fabbri A; Parker L; Colombo C; Mosconi P; Barbara G; Frattaruolo MP; Lau E; Kroeger CM; Lunny C; Salzwedel DM; Mintzes B
    BMJ; 2020 Jan; 368():l6925. PubMed ID: 31969320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Policies on faculty conflicts of interest at US universities.
    Cho MK; Shohara R; Schissel A; Rennie D
    JAMA; 2000 Nov; 284(17):2203-8. PubMed ID: 11056591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Industry Sponsorship With Outcomes of Nutrition Studies: A Systematic Review and Meta-analysis.
    Chartres N; Fabbri A; Bero LA
    JAMA Intern Med; 2016 Dec; 176(12):1769-1777. PubMed ID: 27802480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Financial Conflicts of Interest and Stance on Tobacco Harm Reduction: A Systematic Review.
    Hendlin YH; Vora M; Elias J; Ling PM
    Am J Public Health; 2019 Jul; 109(7):e1-e8. PubMed ID: 31095414
    [No Abstract]   [Full Text] [Related]  

  • 9. Changing conclusions on secondhand smoke in a sudden infant death syndrome review funded by the tobacco industry.
    Tong EK; England L; Glantz SA
    Pediatrics; 2005 Mar; 115(3):e356-66. PubMed ID: 15741361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between author conflicts of interest and industry-sponsorship with the favorability of outcomes of systematic reviews focusing on treatments of erectile dysfunction.
    Corcoran A; Hillman C; Cole T; Anderson M; Weaver M; Johnson BS; Hartwell M; Vassar M
    Andrology; 2021 Nov; 9(6):1819-1827. PubMed ID: 34173351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabis companies and the sponsorship of scientific research: A cross-sectional Canadian case study.
    Grundy Q; Imahori D; Mahajan S; Garner G; Timothy R; Sud A; Soklaridis S; Buchman DZ
    PLoS One; 2023; 18(1):e0280110. PubMed ID: 36626363
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between study sponsorship, risks of bias, and research outcomes in atrazine exposure studies conducted in non-human animals: Systematic review and meta-analysis.
    Bero L; Anglemyer A; Vesterinen H; Krauth D
    Environ Int; 2016; 92-93():597-604. PubMed ID: 26694022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conflicts of interest and critiques of the use of systematic reviews in policymaking: an analysis of opinion articles.
    Forsyth SR; Odierna DH; Krauth D; Bero LA
    Syst Rev; 2014 Nov; 3():122. PubMed ID: 25417178
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alcohol research and the alcoholic beverage industry: issues, concerns and conflicts of interest.
    Babor TF
    Addiction; 2009 Feb; 104 Suppl 1():34-47. PubMed ID: 19133913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond Disclosure: Developing Law and Policy to Tackle Corporate Influence.
    Marks JH
    Am J Law Med; 2020 May; 46(2-3):275-296. PubMed ID: 32659196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Public welfare agenda or corporate research agenda?
    Singh A; Singh S
    Mens Sana Monogr; 2005 Mar; 3(1):41-80. PubMed ID: 22679348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of industry sponsorship and positive outcome in randomised controlled trials in general and abdominal surgery: protocol for a systematic review and empirical study.
    Probst P; Grummich K; Ulrich A; Büchler MW; Knebel P; Diener MK
    Syst Rev; 2014 Nov; 3():138. PubMed ID: 25431307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Managing Conflicts and Maximizing Transparency in Industry-Funded Research.
    Plottel GS; Adler R; Jenter C; Block JP
    AJOB Empir Bioeth; 2020; 11(4):223-232. PubMed ID: 32808880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patient Advocacy Organizations, Industry Funding, and Conflicts of Interest.
    Rose SL; Highland J; Karafa MT; Joffe S
    JAMA Intern Med; 2017 Mar; 177(3):344-350. PubMed ID: 28114624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.